ARTICLE | Clinical News
Intraductal fulvestrant: Phase II started
March 14, 2016 7:00 AM UTC
Atossa began the open-label, U.S. Phase II 007 trial to compare intraductal fulvestrant delivered via its microcatheter device vs. intramuscular Faslodex fulvestrant in about 30 patients who are sche...